However, current FDA-approved c-Met inhibitors include only crizotinib (Xalkori; Pfizer) and cabozantinib (Cometriq; Exelixis) for the treatment of late-stage non-small cell lung cancer (NSCLC) and progressive metastatic medullary thyroid cancer, respectively [12]. Here, MET is linked to non-small cell lung carcinoma.